Posts by Mourabit Halima

Professor Haiwen Huang from The First Affiliated Hospital of Soochow University provided an enlightening discourse on the significant strides made in CAR T cell therapies, with a special emphasis on their pioneering work in FcRH5 CAR-T cells for multiple myeloma. The study not only showcased the remarkable journey of hematology research over the years but also spotlighted the transformative potential of next-generation CAR T cell therapies in offering new hope to patients with hematologic cancers.

In the evolving landscape of hematology and oncology, innovative treatments for challenging conditions like relapsed or refractory marginal zone lymphoma are of paramount importance. It is in this context that the recent phase 2, multicenter, open-label study investigating the efficacy of Orelabrutinib comes to light, marking a significant advancement in the therapeutic domain. This study, meticulously carried out by a dedicated team of researchers led by Professor Haiwen Huang from The First Affiliated Hospital of Soochow University, alongside esteemed colleagues from various prestigious institutions across China, has been a beacon of hope for patients grappling with this relentless malignancy. The findings of this groundbreaking research were meticulously documented in the American Journal of Hematology, underscoring not only the potential of Orelabrutinib as a viable treatment option but also the collaborative effort and expertise that epitomizes the spirit of innovation in the field. This endeavor, emblematic of the strides being made in hematology research, was brilliantly showcased during a session at the renowned Beijing Hematologic Tumor and Immunology Summit Forum, an event that has become a cornerstone for the dissemination of cutting-edge scientific knowledge and clinical practices.

Immunotherapy has recently emerged as a focal area in the research of hematologic oncology. The advancement of genetic engineering and molecular biology, coupled with deeper insights into the mechanisms of cancer, has led to the widespread clinical adoption of Chimeric Antigen Receptor T Cell (CAR-T) therapy. This approach has demonstrated remarkable efficacy in treating refractory or relapsed acute lymphoblastic leukemia, aggressive lymphomas, and multiple myeloma, significantly improving patient outcomes. However, challenges persist, notably in patients who do not respond to treatment, relapse shortly, or experience severe adverse reactions like cytokine release syndrome. The pursuit to mitigate the side effects of CAR-T therapy and enhance its long-term clinical effectiveness is ongoing, filled with both challenges and opportunities.

 Diffuse large B-cell lymphoma (DLBCL) is a typical B-cell lymphoma, characterized by high invasiveness and heterogeneity. After standard first-line treatment, some patients still face relapse/refractory issues and relatively poor prognosis. Recently, the "7th Beijing Thrombosis and Hemostasis Conference and the 5th Beijing Hematology Oncology and Immunology Summit Forum" was successfully held in Beijing from March 1st to 3rd, 2024. After the conference, Oncology Frontier - Hematology Frontier specially invited Professor Jun Zhu from Peking University Cancer Hospital to share the unmet needs of DLBCL patients and their treatment strategies.